Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and Safety of Menatetrenone on Treatment of Postmenopausal Osteoporosis.

Trial Profile

Effect and Safety of Menatetrenone on Treatment of Postmenopausal Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Menatetrenone (Primary) ; Alfacalcidol
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 Dec 2009 Actual number of patients (240) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top